A phase II-a, open-label, randomized study of JX-594 (thymidine kinase-deleted vaccinia virus plus GM-CSF) administered by intratumoral injection in patients with unresectable primary hepatocellular carcinoma.

Trial Profile

A phase II-a, open-label, randomized study of JX-594 (thymidine kinase-deleted vaccinia virus plus GM-CSF) administered by intratumoral injection in patients with unresectable primary hepatocellular carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2016

At a glance

  • Drugs Pexastimogene devacirepvec (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Jennerex
  • Most Recent Events

    • 12 Feb 2013 Results were published in Nature Medicine, according to a Jennerex media release.
    • 03 Jan 2013 Planned end date changed from 1 Dec 2011 to 1 Feb 2013 as reported by ClinicalTrials.gov.
    • 08 Nov 2011 Final data presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top